Pharmacokinetics and Safety Profile of SNS812, a First in Human Fully Modified siRNA Targeting Wide-Spectrum SARS-CoV-2, in Healthy Subjects.

Clin Transl Sci · 2025 · PMC11926758 · PMID 40116355

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Although a decreasing trend in neutrophil count was observed from baseline compared to placebo 4 days post‐dosing at the highest dose of SNS812 in the MAD cohort, there was no significant difference between groups (Figure S1 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.